CALCIUM ACETATE- calcium acetate capsule Rising Pharma Holdings, Inc.

CALCIUM ACETATE CAPSULES USP for Oral Use

These highlights do not include all the information needed to use CALCIUM ACETATE CAPSULES safely and effectively. Please see full prescribing information for CALCIUM ACETATE CAPSULES.

CALCIUM ACETATE capsules, for oral use Initial U.S. Approval: 1990

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use

CALCIUM ACETATE CAPSULES safely and effectively. See full prescribing

information for CALCIUM ACETATE CAPSULES.

CALCIUM ACETATE capsules, for oral use Initial U.S. Approval: 1990 -----INDICATIONS AND USAGE------

• Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease.(1)

-----DOSAGE AND ADMINISTRATION------

- Starting dose is 2 capsules with each meal.(2)
- Titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. Most patients require 3 to 4 capsules with each meal.(2)

-----DOSAGE FORMS AND STRENGTHS------

• Capsule: 667 mg calcium acetate capsule.(3)

-----CONTRAINDICATIONS------

• Hypercalcemia.(4)

------WARNINGS AND PRECAUTIONS------

- Treat mild hypercalcemia by reducing or interrupting calcium acetate and Vitamin D. Severe hypercalcemia may require hemodialysis and discontinuation of calcium acetate.(5.1)
- Hypercalcemia may aggravate digitalis toxicity.(5.2)

-----ADVERSE REACTIONS------

• The most common (> 10%) adverse reactions are hypercalcemia, nausea and vomiting.(6.1)

• In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy.(6)

To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or Safety@lambda-cro.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

-----DRUG INTERACTIONS------DRUG INTERACTIONS------

- Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones.(7)
- When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after calcium acetate or consider monitoring blood levels of the drug.(7)

See 17 for PATIENT COUNSELING INFORMATION

Revised: 09/2022

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- **2 DOSAGE AND ADMINISTRATION**
- **3 DOSAGE FORMS AND STRENGTHS**
- **4 CONTRAINDICATIONS**
- **5 WARNINGS AND PRECAUTIONS**
- 5.1 Hypercalcemia
- 5.2 Concomitant Use with Medications

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Post marketing Experience

7 DRUG INTERACTIONS

7.1 Ciprofloxacin

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Labor and Delivery

8.3 Nursing Mothers

- 8.4 Pediatric Use
- 8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics

13 NONCLINICAL TOXICOLOGY

14 CLINICAL STUDIES

15 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed

1 INDICATIONS AND USAGE

Calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).

2 DOSAGE AND ADMINISTRATION

The recommended initial dose of calcium acetate capsules for the adult dialysis patient is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3 to 4 capsules with each meal.

3 DOSAGE FORMS AND STRENGTHS

Capsule: 667 mg calcium acetate, USP per capsule.

4 CONTRAINDICATIONS

Patients with hypercalcemia.

5 WARNINGS AND PRECAUTIONS

5.1 Hypercalcemia

Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate. Avoid the use of calcium supplements, including calcium based nonprescription antacids, concurrently with calcium acetate.

An overdose of calcium acetate may lead to progressive hypercalcemia, which may require emergency measures. Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the calcium acetate dosage, or discontinue the treatment, depending on the severity of hypercalcemia.

More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy.

Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. Decreasing or discontinuing Vitamin D therapy is recommended as well.

Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long-term effect of calcium acetate on the progression of vascular or soft tissue calcification has not been determined.

Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3-month study of solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment.

Maintain the serum calcium-phosphorus (Ca x P) product below 55 mg2/dL2.

5.2 Concomitant Use with Medications

Hypercalcemia may aggravate digitalis toxicity.

6 ADVERSE REACTIONS

Hypercalcemia is discussed elsewhere [see Warnings and Precautions (5.1)]

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical studies, calcium acetate has been generally well tolerated.

Calcium acetate was studied in a 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and an alternate liquid formulation of calcium acetate was studied in a two-week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients. Adverse reactions (>2% on treatment) from these trials are presented in Table 1.

Table 1: Adverse Reactions in Patients with End-Stage Renal DiseaseUndergoing Hemodialysis

Preferred Term	reactions reported for calcium acetate n=167	3-mo, open- label study of calcium	Double blind, placebo- controlled, cross-over study of liquid calcium acetate n=69			
		n (%)	Calcium acetate n (%)	Placebo n (%)		
Nausea	6 (3.6)	6 (6.1)	0 (0.0)	0 (0.0)		
Vomiting	4 (2.4)	4 (4.1)	0 (0.0)	0 (0.0)		
Hypercalcemia	21 (12.6)	16 (16.3)	5 (7.2)	0 (0.0)		

Mild hypercalcemia may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting. More severe hypercalcemia is associated with confusion, delirium, stupor, and coma. Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate-induced hypercalcemia. Isolated cases pruritus have been reported, which may represent allergic reactions.

6.2 Post marketing Experience

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure. The following additional adverse reactions have been identified during postapproval of calcium acetate: dizziness, edema, and weakness.

7 DRUG INTERACTIONS

The drug interaction of calcium acetate is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl, and hydroxyl groups). Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism.

There are no empirical data on avoiding drug interactions between calcium acetate and most concomitant drugs. When administering an oral medication with calcium acetate where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after calcium acetate. Monitor blood levels of the concomitant drugs that have a narrow therapeutic range. Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate.

7.1 Ciprofloxacin

In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets, approximately 2.7g, decreased the bioavailability of ciprofloxacin by approximately 50%.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C

Calcium acetate capsules contains calcium acetate. Animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [*see Warnings and Precautions (5.1)*]. Maintenance of normal serum calcium levels is important for maternal and fetal well-being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment.

8.2 Labor and Delivery

The effects of calcium acetate on labor and delivery are unknown.

8.3 Nursing Mothers

Calcium acetate is excreted in human milk. Human milk feeding by a mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use


Clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

10 OVERDOSAGE

Administration of calcium acetate in excess of the appropriate daily dosage may result in hypercalcemia [*see Warnings and Precautions (5.1)*].

11 DESCRIPTION

Calcium acetate, USP acts as a phosphate binder. Its chemical name is Calcium acetate, USP. Its molecular formula is C $_4$ H $_6$ CaO $_4$, and its molecular weight is 158.17. Its structural formula is:



Each opaque capsule with a blue cap and white body is spin printed in blue and white ink with "SUVEN" printed on the cap and "667" printed on the body. Each capsule contains 667 mg calcium acetate, USP (anhydrous; Ca(CH $_3$ COO) $_2$; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, and water as the inert binder, crospovidone and sodium stearyl fumarate . The gelatin cap and body have the following inactive ingredients: FD&C blue 1, D&C red 28, titanium dioxide and gelatin. Imprinting ink on capsule body contains shellac and FD&C 2 Aluminum Lake and imprinting ink on capsule cap contains shellac, titanium dioxide and potassium hydroxide. Calcium acetate capsules are administered orally for the control of hyperphosphatemia in end-stage renal failure. Meets USP Dissolution Test 4

12 CLINICAL PHARMACOLOGY

Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. Hyperphosphatemia also plays a role in the development of secondary hyperparathyroidism in patients with ESRD.

12.1 Mechanism of Action

Calcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.

12.2 Pharmacodynamics

Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No carcinogenicity, mutagenicity, or fertility studies have been conducted with calcium acetate.

14 CLINICAL STUDIES

Effectiveness of calcium acetate in decreasing serum phosphorus has been demonstrated in two studies of the calcium acetate solid oral dosage form.

Ninety-one patients with end-stage renal disease who were undergoing hemodialysis and were hyperphosphatemic (serum phosphorus >5.5 mg/dL) following a 1-week phosphate binder washout period contributed efficacy data to an open-label, non-randomized study.

The patients received calcium acetate 667 mg tablets at each meal for a period of 12 weeks. The initial starting dose was 2 tablets per meal for 3 meals a day, and the dose was adjusted as necessary to control serum phosphorus levels. The average final dose after 12 weeks of treatment was 3.4 tablets per meal. Although there was a decrease in serum phosphorus, in the absence of a control group the true magnitude of effect is uncertain.

The data presented in Table 2 demonstrate the efficacy of calcium acetate in the treatment of hyperphosphatemia in end-stage renal disease patients. The effects on serum calcium levels are also presented.

Table 2: Average Serum Phosphorous and Calcium Levels at Pre-Study,					
Interim, and Study Completion Time points					

Parameter	Pre-Study	Week 4 ^b	Week 8	Week 12	p-value ^c
Phosphorous (mg/dL) ^a	7.4 ± 0.17	5.9 ± 0.16	5.6 ± 0.17	5.2 ± 0.17	≤0.01
Calcium	8.9 ± 0.09	9.5 ± 0.10	9.7 ± 0.10	9.7 ± 0.10	≤0.01

^a Values expressed as mean \pm SE.

^b Ninety-one patients completed at least 6 weeks of the study.

^c ANOVA of difference in values at pre-study and study completion.

There was a 30% decrease in serum phosphorus levels during the 12-week study period (p<0.01). Two-thirds of the decline occurred in the first month of the study. Serum calcium increased 9% during the study mostly in the first month of the study.

Treatment with the phosphate binder was discontinued for patients from the open-label study, and those patients whose serum phosphorus exceeded 5.5 mg/dL were eligible for entry into a double-blind, placebo-controlled, cross-over study. Patients were randomized to receive calcium acetate or placebo, and each continued to receive the same number of tablets as had been individually established during the previous study. Following 2 weeks of treatment, patients switched to the alternative therapy for an additional 2 weeks.

The phosphate binding effect of calcium acetate is shown in the Table 3.

Table 3: Serum Phosphorous and Calcium Levels at Study Initiation and AfterCompletion of Each Treatment Arm

Parameter	Pre-Study	Post Treatment	p-value ^b	
	FTE-Study	Calcium Acetate	Placebo	p-value -
Phosphorous (mg/dL) ^a	7.3 ± 0.18	5.9 ± 0.24	7.8 ± 0.22	<0.01
Calcium (mg/dL)a	8.9 ± 0.11	9.5 ± 0.13	8.8 ± 0.12	<0.01

^a Values expressed as mean \pm SEM

^b ANOVA of calcium acetate vs. placebo after 2 weeks of treatment.

Overall, 2 weeks of treatment with calcium acetate statistically significantly (p<0.01) decreased serum phosphorus by a mean of 19% and increased serum calcium by a statistically significant (p<0.01) but clinically unimportant mean of 7%.

16 HOW SUPPLIED/STORAGE AND HANDLING

Calcium Acetate capsules USP, 667 mg are hard gelatin capsules with blue opaque cap imprinted with "SUVEN" in white color ink and a white opaque body imprinted with "667" blue color ink. Each capsule contains 667 mg calcium acetate (anhydrous Ca(CH ₃COO) ₂; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium.

NDC 16571-813-20 Bottles of 200 with child-resistant closure.

STORAGE

Store at 20°-25°C (68°-77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Inform patients to take calcium acetate capsules with meals, adhere to their prescribed diets, and avoid the use of calcium supplements including nonprescription antacids. Inform the patients about the symptoms of hypercalcemia [*see Warnings and Precautions (5.1) and Adverse Reactions (6.1)*].

Advise patients who are taking an oral medication where reduction in the bioavailability of that medication would have clinically significant effect on its safety or efficacy to take the drug one hour before or three hours after calcium acetate capsules.

Manufactured by:

Suven Pharmaceuticals Limited Pashamylaram, Telangana, 502307, India ML No: 24/MD/AP/2009/F/CC

Distributed by:

Rising Pharma Holdings, Inc. East Brunswick, NJ 08816

Revised: 09/2022

Lb50318-3-01

Calcium Acetate Capsules USP

Rising Pharmaceuticals NDC 16571-813-20

Calcium Acetate

Capsules USP

667 mg*

200 Capsules Rx Only

*Each capsule contains: 667 mg calcium

acetate, USP equivalent to 169 mg calcium

DIRECTIONS: SWALLOW CAPSULE. DO NOT

CHEW. Take as directed by your physician.

KEEP THIS AND ALL DRUGS OUT OF REACH

OF CHILDREN.

Store at 20° to 25°C (68° to 77°F); excursions

permitted to 15° to 30°C (59° to 86°F) [See USP

Controlled Room Temperature].

Manufactured By:

Suven Pharmaceuticals Limited Pashamylaram, Telangana, 502307, India

M.L No.: 24/MD/AP/2009/F/CC

Distributed By:

Rising Pharma Holdings, Inc. East Brunswick, NJ, 08816

Lb50318-1-00 Rev. 08/2021



	ACETATE								
calcium aceta	te capsule								
Product In	formation								
Product Type	2	HUMAN PRESCRIPTION DRUG	lte	Item Code (Source)			NDC:1	NDC:16571-813	
Route of Adm	ninistration	ORAL							
Active Ingr	edient/Active	Moiety							
	Ingr	edient Name			Ba	sis of St	rength	Strength	
CALCIUM ACET	TATE (UNII: Y882YX	F34X) (CALCIUM CATION - UNII:2	M83C4F	R6ZB)	CAL	CIUM ACET	ATE	667 mg	
Inactive Inc	aredients								
mactive m	greatents	Ingradiant Nama					C+1	onath	
Ingredient Name D&C RED NO. 28 (UNII: 767IP0Y5NH)						Strength 0.0061 mg			
WATER (UNII: 0	•	vi i /					13.9592	-	
-	D. 1 (UNII: H3R47K3	TBD)					0.0555 ו	-	
					0.0728 mg				
Product Ch	aracteristics								
Color b	lue (Cap, Opaque)	, white (Body,Opaque)	Score	core		score with unever		pieces	
Shape C	APSULE		Size	ize		22mm			
Flavor			Impri	mprint Code Suven;60		Suven;667	57		
Contains									
Packaging									
rackaging				Marke	+ i	. Start	Montro	ting End	
# Item Cod	e Pa	ackage Description		Marketing Start Date		Marketing End Date			
				E	vate	2	Ľ	ate	

1 NDC:16571-813-20

200 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product

11/01/2021



Labeler - Rising Pharma Holdings, Inc. (835513529)

Establishment							
Name	Address	ID/FEI	Business Operations				
Suven Pharmaceuticals Limited		677604288	manufacture(16571-813) , api manufacture(16571-813) , analysis(16571- 813) , pack(16571-813) , label(16571-813)				

Revised: 10/2022

Rising Pharma Holdings, Inc.